Ipsen (FR:IPN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ipsen has expanded its agreement with Exelixis, leveraging promising results from the CABINET Phase III trial to potentially market Cabometyx® for advanced neuroendocrine tumors in territories excluding the U.S. and Japan. The trial showed a significant improvement in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. Ipsen is now in discussions with EU regulatory authorities to pursue marketing authorizations based on these clinical findings.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.